⚠️ Auto-extracted by Claude on 2026-06-25 — closed-access paper (Aging Cell 2006; no PMC OA version identified; gap/no-fulltext-access). Content sourced from PubMed abstract (PMID 16911562) and citation-context from papers that cite this work. Quantitative values (donor counts, correlation r-values) are NOT confirmed from the primary PDF — the abstract does not report specific sample sizes or correlation statistics. Verify all quantitative claims against the primary PDF before relying on them.
Ressler et al. 2006 — p16INK4A is a robust in vivo biomarker of cellular aging in human skin
Closed-access primary study. doi:10.1111/j.1474-9726.2006.00231.x · PMID 16911562. Jansen-Dürr laboratory, Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria; with contributions from Bartek laboratory, Danish Cancer Society Research Center, Copenhagen. Published Aging Cell 2006; 5(5):379–389. Cited ~539 times (top citation percentile).
This paper is the primary human-tissue demonstration that p16INK4A (encoded by CDKN2A) is a robust, in-vivo correlate of cellular aging specifically in human skin. Unlike prior work that drew inferences from rodent models (e.g., krishnamurthy-2004-ink4a-arf-aging-biomarker) or in-vitro fibroblast senescence assays, this study used immunohistochemistry directly on human skin biopsies from donors spanning newborns to nonagenarians, establishing that p16 positivity increases with chronological age in both the dermis and epidermis and that this increase is independent of proliferative markers.
TL;DR
Ressler et al. performed immunohistochemical analysis of human skin biopsies from donors organized into three age groups (0–20 years, 21–70 years, and 71–95 years) drawn from a bank of healthy skin. They found:
- p16INK4A-positive cells increase significantly with age in both the epidermis and dermis
- BMI1 (a Polycomb-group repressor of the Ink4a/Arf locus) is significantly downregulated with increasing donor age — consistent with relief of transcriptional repression at the CDKN2A locus
- Ki67 (a proliferation marker) showed no striking age differences in abundance
- Ki67-positive cells were negative for p16INK4A — confirming mutual exclusion between active proliferation and p16-mediated growth arrest, and that p16+ cells are post-mitotic or growth-arrested rather than cycling
- BMI1-positive cells were also Ki67-negative — consistent with BMI1’s role in regulating quiescent/early-senescent cell states
- These findings support a model in which progressive loss of BMI1-mediated CDKN2A repression drives p16INK4A accumulation with age, leading to irreversible growth arrest of skin cells
Study Design
Tissue source and cohort
| Parameter | Detail |
|---|---|
| Tissue | Human skin biopsies (full-thickness or punch biopsies; route/site not confirmed from abstract) |
| Source | Biobank of healthy human skin (“a bank of healthy human skin”) |
| Age groups | 0–20 years; 21–70 years; 71–95 years |
| n per group | Not confirmed from abstract; gap/needs-fulltext-verification |
| Total donors | Not confirmed from abstract; gap/needs-fulltext-verification |
| Analytic method | Immunohistochemistry (IHC) for p16INK4A, BMI1, Ki67; compartment-specific analysis (epidermis vs dermis) |
| Statistics | Not specified in abstract; significance described qualitatively as “significantly higher” |
Markers assessed
| Marker | Role | Expected age change |
|---|---|---|
| p16INK4A (CDKN2A) | CDK4/6 inhibitor; enforces senescence arrest via p16-rb-pathway | Increase with age (tested) |
| BMI1 | Polycomb-group transcriptional repressor of Ink4a/Arf locus | Decrease with age (tested) |
| Ki67 | Pan-proliferation marker (G1/S/G2/M phases) | No prediction; tested as counter-stain control |
Key Findings
p16INK4A accumulates with age in both skin compartments
The number of p16INK4A-positive cells was significantly higher in elderly donors (71–95 years) compared to younger age groups, in both the epidermis (keratinocyte-dominant) and the dermis (fibroblast/stromal-dominant). This extends the tissue-range of p16 as an aging biomarker from lymphoid and epithelial-secretory tissues (Krishnamurthy 2004) to the human skin specifically, and does so with in-vivo biopsy data rather than cell-culture or rodent readouts.
The paper’s title descriptor — “robust” — is substantiated by the findings in both skin compartments and across the wide age range (newborn to nonagenarian), though the precise effect sizes (fold-changes, percentage positive cells per age group) are not reported in the abstract and require the full PDF for quantitative confirmation. gap/needs-fulltext-verification
BMI1 downregulation with age — a mechanistic corollary
BMI1, a component of the Polycomb repressive complex 1 (PRC1), directly represses the Ink4a/Arf locus. The observation that BMI1 expression is significantly downregulated with increasing donor age provides a mechanistic corollary to the p16 rise: as cells age, epigenetic repression of CDKN2A by BMI1 declines, relieving the brake on p16INK4A expression. This is consistent with:
- Prior work showing Bmi-1 loss in murine skin and hematopoietic tissue with aging
- Krishnamurthy 2004’s model invoking an unknown “coregulator X” alongside Ets-1 — BMI1 loss is a plausible candidate for one component of that coregulatory network
- PRC1 as an epigenetic regulator of the CDKN2A locus across mammalian tissues
Note: whether the BMI1 downregulation precedes or follows p16 accumulation (i.e., whether it is causal or correlative) is not established by this cross-sectional design. gap/no-mechanism (causal direction not established)
Ki67 exclusion — p16+ cells are growth-arrested, not cycling
The mutual exclusion of Ki67 and p16INK4A positivity within the same cells is a critical quality-control result. It confirms that:
- p16INK4A-positive cells are not simply stressed-but-still-cycling cells — they have exited the cell cycle
- The immunohistochemical detection is not an artifact of antibody cross-reactivity
- p16INK4A accumulation specifically marks the growth-arrested fraction, consistent with its mechanistic role as a CDK4/6 inhibitor enforcing G1 arrest via the RB pathway
The observation that BMI1-expressing cells also stained negatively for Ki67 is consistent with BMI1’s known role in regulating quiescent and early-senescent cell states (rather than actively proliferating ones).
Significance as Human Evidence
This paper is one of the two canonical human anchors for p16INK4A as an aging biomarker, alongside:
- Dimri et al. 1995 1 — first cross-sectional human skin data showing SA-β-galactosidase positivity increases with age; limited to n=11 donors; complement (p16 not measured)
- krishnamurthy-2004-ink4a-arf-aging-biomarker — established the tissue-wide rodent evidence; human data in Table 1 is compiled from prior publications, not original
- idda-2020-senescent-markers-human-tissues — later multi-organ human IHC survey; n=5/group; cites this paper for skin validation; independently confirms epidermis p16 rise (~21-fold Young→Old) with largely similar findings
The Ressler 2006 paper is historically positioned as the first study to directly and rigorously document p16INK4A as a human skin aging marker using a broad age range, both skin compartments, and the Ki67/BMI1 co-staining approach. Its ~539 citations reflect sustained adoption as the foundational reference for p16 as a human in-vivo biomarker.
Specific subsequent reliance: Studies that use p16INK4A expression in human skin biopsies as an outcome measure for anti-senescence interventions (e.g., Hickson 2019 dasatinib+quercetin; Justice 2019) trace their biomarker validity directly to Ressler 2006 and Dimri 1995 for the human-skin anchor.
What This Paper Does Not Establish
- Causality: Cross-sectional design; p16 accumulation correlates with donor age but cannot establish that p16 rise causes skin aging or aging-associated skin dysfunction.
- Specific cell types: The abstract does not distinguish fibroblast vs keratinocyte contributions within dermis and epidermis respectively, beyond the compartment designation. Idda 2020’s later finding that skin dermis shows a p21-only pattern (p16 undetectable) contrasts somewhat with Ressler’s dermal p16 signal — a discordance requiring full-PDF reconciliation. gap/contradictory-evidence (epidermis concordant; dermis partially discordant with Idda 2020)
- Comparison with telomere length or other biomarkers: The abstract does not report telomere-length correlation data; whether p16 outperforms telomere length as a skin aging biomarker (as sometimes asserted in review literature citing this paper) cannot be confirmed from the abstract alone. gap/needs-fulltext-verification
- Exact sample sizes and correlation statistics: The abstract does not report n per age group, correlation coefficients, or p-values beyond qualitative significance calls. These are foundational for evidence weighting and must be verified against the primary PDF.
Limitations
- Closed-access paper — primary quantitative data are not confirmable from publicly available sources; reliance on abstract-level extraction creates uncertainty about exact effect sizes. gap/no-fulltext-access
- Cross-sectional cohort — different donors in each age group; inter-individual variation may confound the age signal. The broad age groupings (21–70 years spans 5 decades) may mask within-group heterogeneity.
- Skin only — the “robust biomarker” conclusion applies to skin; generalisation to other tissues requires separate tissue-level studies. Idda 2020 extended this to 10 organs; Krishnamurthy 2004 established the murine multi-tissue context.
- Single-antibody IHC for p16 — no co-staining for additional senescence markers (γH2AX, lamin B1 loss, SA-β-gal, SASP cytokines); p16 positivity alone does not formally confirm the full senescence signature by current multi-marker criteria.
- Skin-site specificity — donor skin biopsy sites are not confirmed from the abstract; photoexposed vs photoprotected skin may show different p16 accumulation trajectories (UV exposure is an acute activator of p16).
Cross-references
- p16-rb-pathway — pathway page that incorporates this study as the primary human skin-tissue anchor for in-vivo p16 aging biology
- cellular-senescence — hallmark page; this study is cited as direct human evidence of senescent cell accumulation in skin
- cellular-senescence — hallmark MOC
- krishnamurthy-2004-ink4a-arf-aging-biomarker — the complementary rodent multi-tissue foundational paper; Ressler 2006 is the human-skin counterpart
- idda-2020-senescent-markers-human-tissues — later multi-organ human survey that independently confirms the epidermal p16 signal and adds 9 other organs; notes dermis is p21-dominant (not p16), a possible discordance with this paper
- cellular-senescence — if a process page exists; p16 as senescence marker
- skin — if a tissue page exists; this study is the canonical p16 biomarker anchor for skin tissue
Footnotes
Footnotes
-
doi:10.1073/pnas.92.20.9363 · Dimri GP et al. · PNAS 1995 · observational · model: human fibroblasts + human skin biopsies (n=11) · original establishment of SA-β-gal as senescence biomarker; first cross-sectional human skin senescence data ↩